Inotuzumab ozogamicin, an anti-CD22–calecheamicin conjugate, for refractory and relapsed acute lymph...
Inotuzumab ozogamicin, an anti-CD22–calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study
About this item
Full title
Author / Creator
Kantarjian, Hagop, Prof , Thomas, Deborah, MD , Jorgensen, Jeffrey, MD , Jabbour, Elias, MD , Kebriaei, Partow, MD , Rytting, Michael, MD , York, Sergernne, RN , Ravandi, Farhad, MD , Kwari, Monica, RN , Faderl, Stefan, MD , Rios, Mary Beth, RN , Cortes, Jorge, MD , Fayad, Luis, MD , Tarnai, Robert, PhD , Wang, Sa A, MD , Champlin, Richard, MD , Advani, Anjali, MD and O'Brien, Susan, MD
Publisher
England: Elsevier Ltd
Journal title
Language
English
Formats
Publication information
Publisher
England: Elsevier Ltd
Subjects
More information
Scope and Contents
Contents
Summary Background The outlook for patients with refractory and relapsed acute lymphocytic leukaemia (ALL) is poor. CD22 is highly expressed in patients with ALL. Inotuzumab ozogamicin is a CD22 monoclonal antibody conjugated to the toxin calecheamicin. We did a phase 2 study to assess the efficacy of this antibody. Methods We recruited patients at...
Alternative Titles
Full title
Inotuzumab ozogamicin, an anti-CD22–calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study
Authors, Artists and Contributors
Author / Creator
Thomas, Deborah, MD
Jorgensen, Jeffrey, MD
Jabbour, Elias, MD
Kebriaei, Partow, MD
Rytting, Michael, MD
York, Sergernne, RN
Ravandi, Farhad, MD
Kwari, Monica, RN
Faderl, Stefan, MD
Rios, Mary Beth, RN
Cortes, Jorge, MD
Fayad, Luis, MD
Tarnai, Robert, PhD
Wang, Sa A, MD
Champlin, Richard, MD
Advani, Anjali, MD
O'Brien, Susan, MD
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_1017956997
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_1017956997
Other Identifiers
ISSN
1470-2045
E-ISSN
1474-5488
DOI
10.1016/S1470-2045(11)70386-2
